drugset / Trial / NCT00030186
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.
Timeline
- Start
- 2002-01
- Primary completion
- 2003-02
- Completion
- 2003-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lestaurtinib | Small molecule | 40 mg | Oral |
| Subject | lestaurtinib | Small molecule | 60 mg | Oral |
| Subject | lestaurtinib | Small molecule | 80 mg | Oral |